Increasing SCN1A expression with antisense oligonucleotides or with AAV‐9‐based gene therapy has been successful in mouse models of Dravet syndrome (Han et al., 2020; Lim et al., 2020; Tanenhaus et al., 2022), and trials in humans are underway (Sullivan & Wirrell, 2023). Here, SCN1A is linked to encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.